Cuong Nguyen, MD
Nephrology · Norman, OKNPI 1659497451
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for nephrology clinicians in OK, where the typical reported total is $2,111.
Across 116 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$488
- AstraZeneca$445
- Amgen$281
- Otsuka America Pharmaceutical, Inc.$203
- Outset Medical Inc$117
- Bayer$111
- plus $653 from 18 others
What the payments were for
- Food & beverage$2,15894%
- Education$1406%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 30 | $488 |
| AstraZeneca | 21 | $445 |
| Amgen(2 entities) | 17 | $281 |
| Otsuka America Pharmaceutical, Inc. | 10 | $203 |
| Outset Medical Inc | 1 | $117 |
| Bayer | 5 | $111 |
| Ardelyx, Inc. | 4 | $81 |
| GSK | 4 | $74 |
| Akebia Therapeutics Inc | 5 | $59 |
| Calliditas Therapeutics US Inc. | 2 | $48 |
| Pharmacosmos Therapeutics Inc. | 2 | $45 |
| Novo Nordisk | 2 | $42 |
| Shield Therapeutics Inc | 1 | $42 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Vifor Pharma, Inc. | 2 | $28 |
| Lilly USA, LLC | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $28 |
| Novartis | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| OPKO Pharmaceuticals, LLC | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,298 in reported general payments places this provider in the 50th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 19 | $68,085 |
| VeltassaPatiromer Calcium Sorbitex | 47 | $46,856 |
| LokelmaSodium Zirconium Cyclosilicate | 39 | $33,403 |
| Tolvaptan | 13 | $31,953 |
| FarxigaDapagliflozin Propanediol | 29 | $26,365 |
| Sevelamer Carbonate | 76 | $26,140 |
| Febuxostat | 48 | $7,093 |
| Potassium Citrate ErPotassium Citrate | 16 | $3,554 |
| Allopurinol | 258 | $2,704 |
| Torsemide | 77 | $2,464 |
| Calcium Acetate | 15 | $1,681 |
| Lisinopril | 220 | $1,654 |
| Potassium Chloride | 40 | $1,422 |
| Hydralazine Hcl | 69 | $1,243 |
| Carvedilol | 120 | $1,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma, Farxiga | $445 | $59,76968 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan | $28 | $31,95313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Norman
- David WilliamsNorman$6K
- Kendral KnightNorman$2K
- Celeste BoeckmanOklahoma City$90K
- Joseph GhataOklahoma City$45K
- Sunil AgrawalTulsa$40K
- Benjamin CowleyOklahoma City$36K
- Pranay KathuriaTulsa$21K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Brad CarterOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.